Nanexa extends collaboration agreement with Applied Materials
Nanexa AB (publ) today announced that the company has expanded its collaboration agreement with Applied Materials, Inc., through an amendment regulating commercial arrangements, paving the way for potential future license agreements with customers in the pharmaceutical industry.
The agreement sets the framework for utilizing the respective strengths of the two companies to accelerate advanced drug development in relation to potential future agreements covering both licensing and commercial production of drugs. The collaboration builds on Nanexa’s expertise and exclusivity in the field of parenteral drug development and Applied’s deep expertise in materials engineering and advanced manufacturing technologies.
In December 2020, Nanexa signed a collaboration agreement with Applied Materials for joint development of coating technology, in order for Nanexa to secure larger scale manufacturing capabilities for its ALD-coated long-acting injectable drugs.
This agreement builds in its entirety on the previously communicated collaboration agreement.
"We highly value the collaboration with Applied Materials as it helps accelerate our efforts to take a project from idea all the way to market production," says David Westberg, CEO of Nanexa. “The expanded agreement follows the completion of Nanexa’s new pilot plant and gives us good momentum as we seek to engage further with customers.